Earnings ·
On August 13, 2026, 4D Molecular Therapeutics reported second-quarter financial results showing a net loss of $72.9…
FDMT4D Molecular Therapeutics, Inc.
On August 13, 2026, 4D Molecular Therapeutics reported second-quarter financial results showing a net loss of $72.9 million on collaboration revenue of $3.8 million. The company secured a strategic credit facility with Hercules Capital for up to $200 million, drawing an initial $20 million at closing. Cash and marketable securities totaled $430.6 million as of June 30, 2026, sufficient to fund operations into the second half of 2028. Operational highlights include completed enrollment for the Phase 3 4FRONT-2 trial in wet AMD, with topline data expected in H2 2027, and positive two-year PRISM Phase 2b data presented at ASRS. The company plans to initiate a Phase 3 trial for diabetic macular edema in Q3 2026 and will host an Investor Day on October 21, 2026. 4D Molecular Therapeutics is a late-stage biotechnology company developing gene therapies for retinal diseases.